BioMarin Pharmaceutical (BMRN) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioMarin Pharmaceutical (BMRN) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 0.9% versus a loss of 12.5%. Over five years, RDY leads with a -7.1% price change compared with -27.3% for BMRN. BioMarin Pharmaceutical is the larger company by market cap ($10.50 billion vs $10.04 billion), about 1.0 times the size, while Dr. Reddy's Laboratories is growing revenue faster (+13.8% vs +12.9%).
On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (8.2x vs 18.7x for Dr. Reddy's Laboratories). Dr. Reddy's Laboratories pays a dividend yielding 66.36%, while BioMarin Pharmaceutical does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus 10.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRN | RDY |
|---|---|---|
| Share price | $54.25 | $12.06 |
| Market cap | $10.50B | $10.04B |
| 1-day change | -1.72% | -1.75% |
| YTD return | -7.12% | -12.61% |
| 1-year return | +0.91% | -12.54% |
| 5-year return | -27.26% | -7.06% |
| P/E ratio (TTM) | 146.62 | 27.40 |
| Forward P/E | 8.18 | 18.71 |
| EPS (TTM) | $0.37 | $0.44 |
| Dividend yield | 0.00% | 66.36% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $3.22B | $3.81B |
| Revenue growth (YoY) | +12.87% | +13.76% |
| Net income (latest FY) | $348.90M | $663.00M |
| Gross margin | 77.73% | 58.51% |
| Operating margin | 12.71% | 22.09% |
| Net margin | 10.83% | 17.40% |
| 52-week high | $70.98 | $15.67 |
| 52-week low | $49.26 | $11.36 |
| Distance from 52-week high | -23.57% | -23.07% |
| Analyst consensus | buy | none |
| Avg. price target upside | +68.88% | +9.66% |
| Average volume | 2.01M | 2.89M |
| Shares outstanding | 193.57M | 832.99M |
| Employees | 3,221 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMRN has outperformed RDY by 13.5 percentage points over the past year.
- BioMarin Pharmaceutical trades at a higher earnings multiple (146.6x vs 27.4x trailing P/E).
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (66.36% vs 0.00%).
- Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus 10.8 cents for BioMarin Pharmaceutical.
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
BMRN vs RDY FAQ
Which is bigger, BioMarin Pharmaceutical or Dr. Reddy's Laboratories?
BioMarin Pharmaceutical (BMRN) is larger, with a market capitalization of $10.50B compared with $10.04B for Dr. Reddy's Laboratories (RDY).
Which stock has performed better over the past year, BMRN or RDY?
BMRN returned +0.91% over the past 12 months, compared with -12.54% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMRN or RDY?
RDY has the lower trailing P/E at 27.4, versus 146.6 for BMRN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, BioMarin Pharmaceutical or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 66.36%, while BioMarin Pharmaceutical does not currently pay a regular dividend.
Are BioMarin Pharmaceutical and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.